These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29750700)

  • 1. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
    Ditzel HM; Strickland KC; Meserve EE; Stover E; Konstantinopoulos PA; Matulonis UA; Muto MG; Liu JF; Feltmate C; Horowitz N; Berkowitz RS; Gupta M; Hecht JL; Lin DI; Jochumsen KM; Welch WR; Hirsch MS; Quade BJ; Lee KR; Crum CP; Mutter GL; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2019 May; 38(3):230-240. PubMed ID: 29750700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
    J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
    Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
    Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
    Michaan N; Chong WY; Han NY; Lim MC; Park SY
    Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Ki-67 Labeling Index on Prognostic Significance of the Chemotherapy Response Score in Women With Tubo-ovarian Cancer Treated With Neoadjuvant Chemotherapy.
    Heayn M; Skvarca LB; Zhu L; Edwards RP; Olawaiye AB; Modugno F; Elishaev E; Bhargava R
    Int J Gynecol Pathol; 2021 May; 40(3):278-285. PubMed ID: 32897953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma.
    Said I; Böhm S; Beasley J; Ellery P; Faruqi AZ; Ganesan R; Hirschowitz L; Jeetle S; Leen SL; McCluggage WG; McDermott J; Merard R; Millner TO; Trevisan G; Vella J; Gilks CB; Singh N
    Int J Gynecol Pathol; 2017 Mar; 36(2):172-179. PubMed ID: 27362902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
    Okoye E; Euscher ED; Malpica A
    Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression.
    Roseland ME; Ma T; Shampain KL; Stein EB; Wasnik AP; Curci NE; Sciallis AP; Uppal S; Johnson TD; Maturen KE
    Abdom Radiol (NY); 2024 Jun; 49(6):2040-2048. PubMed ID: 38478037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis.
    Santoro A; Travaglino A; Inzani F; Straccia P; Arciuolo D; Valente M; D'Alessandris N; Scaglione G; Angelico G; Piermattei A; Cianfrini F; Raffone A; Zannoni GF
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
    BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
    Kojima N; Kuno I; Ushigusa T; Kato T; Yoshida H
    Virchows Arch; 2020 Sep; 477(3):429-436. PubMed ID: 32103350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.
    Santoro A; Angelico G; Piermattei A; Inzani F; Valente M; Arciuolo D; Spadola S; Mulè A; Zorzato P; Fagotti A; Scambia G; Zannoni GF
    Front Oncol; 2019; 9():778. PubMed ID: 31482065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.